AstraZeneca Acquires EsoBiotec for $1B, Advancing In Vivo Cell Therapy

Published on Spencer Knight via LinkedIn

AstraZeneca has acquired Belgian biotech EsoBiotec for $1 billion, including $425 million upfront, reinforcing its position in cell and gene therapy. The deal focuses on EsoBiotec’s ENaBL platform, which uses lentiviral vectors to engineer immune cells directly inside the patient’s body through a simple IV injection.

This acquisition underscores AZ’s growing commitment to CGT and reflects the potential of in vivo cell therapies to simplify delivery, reduce cost, and speed up access. Spencer Knight notes this is AZ’s second major CT deal in a week, marking a surge of pharma confidence in the sector.

Read the full post on LinkedIn:

👉 Spencer Knight: AZ makes $1 Billion In Vivo Cell Therapy Acquisition

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full details, please refer to the original article via the provided link.